According to the most recent 13F filing that Kornitzer Capital Management Inc. made with the Securities and Exchange Commission on behalf of Boston Scientific Co. (NYSE: BSX), the company’s holdings in Boston Scientific Co. experienced a decrease of 4.0 percent during the third quarter (SEC). The corporation finished the reporting period with a total of 400,814 shares of the stock held by the medical equipment provider, following the sale of 16,866 of those company’s shares. Kornitzer Capital Management Inc. (KS), as of the end of the most recent reporting period, held an equity position in Boston Scientific valued at $15,524,000.
During the past few months, several other significant investors have made purchases and/or sales of BSX stock. The percentage of Newport Trust Company’s holdings allocated to Boston Scientific experienced a 5,082.5% increase during the second quarter. The medical equipment provider’s stock has a current market value of $275,866,00, and Newport Trust Co. has recently acquired ownership of 7,401,817 shares of the company’s stock. This is because the company made an additional purchase of 7,258,993 shares during the time above, a period of Newport Trust Company’s holdings that were allocated to Boston Scientific experienced a 5,082.5% increase during the second quarter. The medical equipment provider’s stock has a current market value of $275,866,00, and Newport Trust Co. has recently acquired ownership of 7,401,817 shares of the company’s stock. This is because the company made an additional purchase of 7,258,993 shares during the period above. During the second quarter, DZ Bank AG, also known as Deutsche Zentral Genossenschaftsbank Frankfurt am Main, acquired an additional 24.5% ownership in Boston Scientific. This brought the total percentage of ownership held by the bank to 75%. DZ BANK AG, Deutsche Zentral Genossenschaftsbank Frankfurt am Main, has a total of 20,806,144 shares of the stock held by the medical equipment provider as a result of the purchase of an additional 4,088,589 shares during the quarter. These shares have a value of $775,455,000 collectively. During the second quarter, Lazard Asset Management LLC achieved a 23.6% increase in the share of ownership in Boston Scientific before this time.
Lazard Asset Management LLC now holds 12,653,052 shares of the medical equipment provider’s stock following the acquisition of an additional 2,416,974 shares. The stock currently has a total value of $471,578,000 due to the total number of shares held. Arrowstreet Capital Limited Partnership successfully acquired an additional 65.9 percent of the stock in Boston Scientific during the first three months of the year. Arrowstreet Capital Limited Partnership now owns 5,430,814 shares of the medical equipment provider’s stock after purchasing an additional 2,157,849 shares during the most recent quarter. This brings the total number of shares owned by the firm to 5,430,814. The price at which these shares are currently trading is equivalent to 240,531,000 dollars.
Last but not least, during the second quarter, Artisan Partners Limited Partnership increased the number of Boston Scientific shares in its portfolio by 10.6%. Artisan Partners Limited Partnership now owns 19,323,700 shares of the medical equipment provider’s stock, which have an estimated market value of $720,194,000 following the purchase of an additional 1,849,604 shares during the most recent quarter. The majority of the company’s shares, or 90.23 percent, are currently held by hedge funds and other institutional investors.
The price of one share of NYSE: BSX was $45.40, reflecting a loss of $0.06 since midday on Friday. The company’s stock was involved in 40,726 transactions, with an average volume of 7,516,874 shares traded each time. Over the previous twelve months, the price of a share of Boston Scientific Company ranged from $34.98 to $47.95, with an average price of $47.95. The moving average price of the stock over the past 200 days is $42.16; the moving average price over the last fifty days is $45.35. The company has the following financial metrics:
A price-to-earnings ratio of 2.35
A price-to-earnings-growth ratio of 2.35
A beta value of 0.83
A market value of $65.03 billion
A PE ratio of 108.22
A price-to-earnings-growth ratio of 2.35
There is currently a debt-to-equity ratio of 0.49, a quick ratio of 0.95, and a current ratio of 1.45. All three of these ratios are at their respective historic lows.
On October 26th, Boston Scientific (NYSE: BSX) released its most recent quarterly earnings report. The manufacturer of medical equipment reported earnings per share for the quarter of $0.43, which was below the $0.44 average forecast by a margin of earnings per share for the quarter of $0.43, which was below the $0.44 average forecast by a margin of $0.05 The manufacturer of medical equipment reported earnings per share for the quarter of $0.43, which was below the $0.44 average forecast by a margin of $0.05. Boston Scientific successfully achieved a return on equity of 14.55%, and its net margin reached 5.19%. The actual revenue the company brought in for the quarter was $3.17 billion, which is higher than the $3.14 billion revenue forecast for the company throughout the quarter. The company reported a profit of $0.41 per share for the same period in the previous year’s financial statements. Compared to the same quarter in the previous year, the increase in revenue was 8.1% higher than expected. Analysts specializing in equity research anticipate that the Boston Scientific Company will generate $1.73 per share in 2018.
Several analysts’ reports include contributions from those analysts regarding their thoughts on BSX. In a research note published on StockNews.com on October 12th, the company announced that it would start covering shares of Boston Scientific. They recommended that shareholders “hold” their shares of the company. December 22nd saw the publication of a research note by Mizuho, which signaled the beginning of the firm’s coverage of shares of Boston Scientific. They have provided the business with a “neutral” rating and have established a price objective for the stock of $52.00. In a research note published on Friday, October 28th, Canaccord Genuity Group raised both their “buy” rating for Boston Scientific and their price objective on the stock, which went from $45.00 to $48:00. Both of these changes were made. The email discussed an assessment of the stock market. Raymond James raised their price objective on Boston Scientific by $8, moving it up to $54.00 from $48.00 in a research note published on December 8th. At long last, on December 20th, Citigroup announced in a research note that it would start covering shares of Boston Scientific. The announcement had been anticipated for quite some time. They recommended that the company “buy” the stock and establish a price objective of $54.00. Three research experts suggest maintaining a holding position in the stock; twelve analysts suggest purchasing the stock, and one analyst suggests a strong purchase of the stock. According to Bloomberg.com, the stock is currently rated a “Moderate Buy” by the consensus, and the consensus price goal is currently set at $50.00. Additionally, the consensus price target was set in the past.
In other news, Executive Vice President Wendy Carruthers sold 1,678 company stock on November 15th. This was reported in the news on November 15th. This information was shared in a public announcement made by the company. The sale of the stock resulted in total revenue of $71,482.80, with the average price that each share was able to fetch being $42.60. Following the completion of the transaction, the executive vice president will have a total of 94,913 shares of the company’s stock, each of which is currently estimated to be worth $4,043,293.80. The Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC.
On top of that, Executive Vice President Jeffrey B. Mirviss sold 11,080 shares of the company’s stock on December 12th. The amount of stock sold came to a total of $517,990.00, and the price received per share, which was the average selling price, was $46.75. Following the sale of a portion of his holdings, the company’s executive vice president currently possesses 88,479 shares of the company’s stock, which have a combined value of approximately $4,136,393.25. Information regarding the sale submitted to the Securities and Exchange Commission can be accessed online through the SEC’s website 15th. This information was shared in a public announcement made by the company. The sale of the stock resulted in total revenue of $71,482.80, with the average price that each share was able to fetch being $42.60. Following the completion of the transaction, the executive vice president will have a total of 94,913 shares of the company’s stock, each of which is currently estimated to be worth $4,043,293.80. The Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC.
On top of that, Executive Vice President Jeffrey B. Mirviss sold 11,080 shares of the company’s stock on December 12th. The amount of stock sold came to a total of $517,990.00, and the price received per share, which was the average selling price, was $46.75. Following the sale of a portion of his holdings, the company’s executive vice president currently possesses 88,479 shares of the company’s stock, which have a combined value of approximately $4,136,393.25. Information regarding the sale submitted to the Securities and Exchange Commission can currently be accessed online through the SEC’s website. Furthermore, Executive Vice President Wendy Carruthers sold 1,678 Boston Scientific stock on November 15th. On the same day, these shares were bought and sold. There was a total transaction of $714,82.80 worth of the company’s stock, with each share selling for an average price of $42.60. After the deal’s completion, the executive vice president gained direct ownership of 94,913 shares of company stock, which have a combined value of $4,043,293.80. Disclosures that are related to the sale might be found in this section of the website. Insiders of a company have sold a total of $9,561,634 worth of company stock over the past three months, resulting in the disposal of 220,265 shares. The current percentage of the company’s stock held by company insiders is 0.66 percent.
The Boston Scientific Corporation is in the business of designing, manufacturing, and distributing medical devices that are utilized in a wide variety of interventional medical specialties all over the world. These devices can be found in over 100 countries. Three distinct areas are covered, and they are as follows: cardiovascular, rhythm and neuro, and medical surgery. The company offers a vast selection of medical devices, some of which include implantable cardioverter and implantable cardiac resynchronization therapy defibrillators, pacemakers and implantable cardiac resynchronization therapy pacemakers, remote patient management systems, devices for diagnosing and treating gastrointestinal and pulmonary conditions, devices for treating various urological and pelvic conditions, and many more.
